ReferenceCitation: Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT(†). Ann Oncol. 2021 Mar;32(3):404-411. doi: 10.1016/j.annonc.2020.11.019. Epub 2020 Dec 3.

family: Cottereau

full_name: A.-S. Cottereau

family: Meignan

full_name: M. Meignan

given: M.

family: Nioche

full_name: C. Nioche

given: C.

family: Capobianco

full_name: N. Capobianco

given: N.

family: Clerc

full_name: J. Clerc

given: J.

family: Chartier

full_name: L. Chartier

given: L.

family: Vercellino

full_name: L. Vercellino

family: Casasnovas

full_name: O. Casasnovas

given: O.

family: Thieblemont

full_name: C. Thieblemont

family: Buvat

full_name: I. Buvat

given: I.

journal_name: Annals of Oncology

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inria

repository_normalized: HAL

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Diderot

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

title: Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†

ReferenceCitation: Vercellino L, Cottereau AS, Casasnovas O, Tilly H, Feugier P, Chartier L, Fruchart C, Roulin L, Oberic L, Pica GM, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O, Sebban C, López-Guillermo A, Sanhes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Briere J, Salles G, Gaulard P, Meignan M, Thieblemont C. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020 Apr 16;135(16):1396-1405. doi: 10.1182/blood.2019003526.

name: Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Nuclear Medecine, Paris, France;

full_name: Laetitia Vercellino

given: Laetitia

name: Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Nuclear Medecine, René Descartes University, Paris, France;

full_name: Anne-Segolene Cottereau

given: Anne-Segolene

name: Service d’Hématologie Clinique, Centre Hospitalier Universitaire Dijon, INSERM UMR1231, Dijon, France;

full_name: Olivier Casasnovas

given: Olivier

name: Department of Hematology, Centre Henri Becquerel, University Rouen, INSERM U1245, Rouen, France;

family: Tilly

full_name: Hervé Tilly

given: Hervé

name: Department of Hematology, Centre Hospitalier Universitaire Nancy, INSERM 1256, Nancy, France;

family: Feugier

full_name: Pierre Feugier

given: Pierre

name: The Lymphoma Academic Research Organisation, Statistic, Centre Hospitalier Lyon Sud, Pierre-Benite, France;

full_name: Loic Chartier

given: Loic

name: Hématologie, Institut d’Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen, France,

family: Fruchart

full_name: Christophe Fruchart

given: Christophe

name: University Hospital Henri-Mondor Assistance Publique-Hôpitaux de Paris, Creteil, France;

family: Roulin

full_name: Louise Roulin

given: Louise

name: Hôpital de Purpan, Centre Hospitalier Universitaire Toulouse, Toulouse, France;

family: Oberic

full_name: Lucie Oberic

given: Lucie

name: Department of Hematology, Centre Hospitalier Métropole Savoie Chambéry, Chambéry, France;

family: Pica

full_name: Gian Matteo Pica

given: Gian Matteo

name: Hematology, Institut Gustave Roussy, Villejuif, France;

name: Centre Hospitalier Universitaire Dupuytren, Limoges, France;

name: Institut Jules Bordet, Brussels, Belgium;

name: Centre Hospitalier René Dubos, Pontoise, France;

name: Department of Hematology, Institut Paoli Calmettes, Marseille, France;

name: Hematology/Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France;

name: Hematologie, Centre Leon Berard, Lyon, France;

name: Hematology, Hospital Clinic Barcelona, Barcelona, Spain;

name: Hematology, Centre Hospitalier Marechal Joffre–Hôpital Saint-Jean, Perpignan, France;

name: Hematology, Université Lille, Centre Hospitalier Universitaire Lille, EA 7365 Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France;

name: Concord Repatriation General Hospital, University of Sydney, Concord NSW, Australia;

name: Service d’Hématologie Clinique, Centre Hospitalier Regional Annecy, Annecy, France;

name: Hematology, Centre Hospitalier Dr Duchenne, Boulogne-Sur-Mer, France;

name: Hematology, Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium;

name: Hematology, Centre Hospitalier Bretagne Atlantique, Vannes, France;

name: Pathology, INSERM U955, University Hospital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France;

name: Department of Hematology, INSERM U1052 Hospices Civils de Lyon, University of Lyon, Pierre-Bénite, France;

name: Pathology, INSERM U955, University Hospital Henri-Mondor Assistance Publique-Hôpitaux de Paris, Créteil, France,

name: Lymphoma Study Association-Imaging, Hospital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, University Paris-Est Créteil, Créteil, France;

name: Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Hemato-Oncology, Paris, France; and

name: Sorbonne Paris Cité, Diderot University, Paris, France

location_country: Austria Switzerland Spain France Poland Israel Australia Belgium Portugal

location_facility: Universite Catholique de Louvain Mont Godinne

location_facility: Hôpital des instructions des Armées PERCY

location_facility: SPZOZ Zespol Szpitali Miejskich w Chorzowie

location_facility: Rabin Medical Center - Beilinson Hospital

location_facility: Hospital Général Universitario Gregorio Maranon

location_facility: Hospital Universitario Fundacion Alcorcon

location_facility: Clinique Victor Hugo - Centre Jean Bernard

location_facility: Landeskrankenhaus Steyr - Innere Medizin II

location_facility: Frankston Hospital Monash Medical Centre

location_facility: Centre Hospitalier Universitaire Vaudois

location_facility: Krankenhaus Barmherzigen Schwestern Linz - Abteilung für Inner

location_facility: AKh Linz - Innere Medizin 3 - Zentrum für Hämatologie un

location_facility: Oddzial Chorob Rozrostowych Regionalny Osrodek Onkologiczny

location_facility: Instituto Português de Oncologia de Lisboa de Francisco Gentil

location_facility: AZ Groeninge - Campus Maria s Voorzienigheid

location_facility: Medizinische Universität Innsbruck für Innere Medizin

location_facility: Albury Base Hospital/Murray Valley Private Hospital

location_facility: Klinika Nowotworow Ukladu Chlonnego- Centrum Onkologii

location_facility: Complejo Hospitalario Universitario de A Coruna

location_facility: Klinika Hematologii Collegium Medicum UJ

location_facility: Hopital Universitario Virgen de la Arrixaca

location_facility: Flinders Medical Centre - Repatriation General Hospital

location_facility: Universitätklinik der PMU Salzburg - Für Innere Medizin III

location_facility: Universite Catholique de Louvain Saint Luc

location_facility: Mater Misericordiae Hospital - Calvary Mater NewCastle

location_facility: LKH Leoben-Eisenerz Department für Hämato-Onkologie

title: Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line

summary:
This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to explore the effect of maintenance therapy with lenalidomide versus placebo on progression-free survival (PFS) in patients treated with R-CHOP responding to induction therapy

For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs 73.6%), is considered clinically relevant.


ReferenceType: derived

ReferenceCitation: Cortes J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez N, Chao TC, Espié M, Nabholtz JM, Gonzàlez Farré X, Beliakouski V, Román García J, Holgado E, Campone M. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2018 Apr 1;29(4):881-887. doi: 10.1093/annonc/mdy051.

family: Cortes

full_name: J. Cortes

sequence: first

family: Perez-Garcia

full_name: J. Perez-Garcia

sequence: additional

family: Levy

full_name: C. Levy

family: Gómez Pardo

full_name: P. Gómez Pardo

given: P.

family: Bourgeois

full_name: H. Bourgeois

given: H.

family: Spazzapan

full_name: S. Spazzapan

given: S.

family: Martínez-Jañez

full_name: N. Martínez-Jañez

family: Chao

full_name: T.-C. Chao

family: Espié

full_name: M. Espié

given: M.

family: Nabholtz

full_name: J.M. Nabholtz

family: Gonzàlez Farré

full_name: X. Gonzàlez Farré

given: X.

family: Beliakouski

full_name: V. Beliakouski

given: V.

family: Román García

full_name: J. Román García

family: Holgado

full_name: E. Holgado

given: E.

family: Campone

full_name: M. Campone

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

oa_host_type: publisher

evidence: open (via crossref license)

host_type: publisher

license: elsevier-specific: oa user license

license_normalized: elsevier-specific

version: publishedVersion

design_allocation: Randomized

intervention_type: Drug

status: Completed

study_start_date_type: Actual

study_type: Interventional

lead_sponsor: Pierre Fabre Medicament

enrollment_type: Actual

primary_purpose: Treatment

location_country:
Italy
Austria
South Africa
Spain
France
Argentina
Belgium
Russian Federation
Belarus
Germany
United Kingdom
Taiwan
Portugal
Ukraine

study_completion_date_type: Actual

source: euctr

title: Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0)

summary: In metastatic breast cancer (MBC) patients who have already received anthracyclines, taxanes, antimetabolites and vinca-alkaloids and have developed drug resistance to these drugs, therapeutic options are very limited. Alkylating agents showed a modest activity in pretreated metastatic breast cancer. This phase III trial will compare the effectiveness and the safety profile of vinflunine to an alkylating agent of physician choice in MBC patients who have exhausted anthracyclines, taxanes, antimetabolites and vinca-alkaloids.

lead_sponsor_type: industriel

status_simplified: Completed


title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).

summary: The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.

ReferenceCitation: Rabe KF, Halpin DMG, Han MK, Miravitlles M, Singh D, Grönke L, Voß F, Martinez FJ. Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respir Res. 2020 Jul 9;21(1):177. doi: 10.1186/s12931-020-01431-y.

family: Rabe

full_name: Klaus F. Rabe

given: Klaus F.

family: Halpin

full_name: David M. G. Halpin

given: David M. G.

family: Han

full_name: MeiLan K. Han

given: MeiLan K.

family: Miravitlles

full_name: Marc Miravitlles

given: Marc

family: Singh

full_name: Dave Singh

given: Dave

family: Grönke

full_name: Lars Grönke

given: Lars

family: Voß

full_name: Florian Voß

given: Florian

family: Martinez

full_name: Fernando J. Martinez

given: Fernando J.

currency_apc_doaj: GBP

journal_name: Respiratory Research

oa_colors: green gold

oa_host_type: publisher;repository

evidence: oa journal (via doaj)

license: cc-by

license_normalized: cc-by

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

repository_institution: ZB MED - Informationszentrum Lebenswissenschaften - PUBLISSO-Fachrepositorium Lebenswissenschaften

evidence: oa repository (via pmcid lookup)

license_normalized: no license

repository_normalized: PubMed Central

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

publisher_normalized: Springer

ReferenceCitation: Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial. Respir Res. 2018 Oct 5;19(1):196. doi: 10.1186/s12931-018-0874-0.

family: Tashkin

full_name: Donald P. Tashkin

given: Donald P.

family: Celli

full_name: Bartolomé R. Celli

given: Bartolomé R.

family: Metzdorf

full_name: Norbert Metzdorf

given: Norbert

family: Mueller

full_name: Achim Mueller

given: Achim

family: Anzueto

full_name: Antonio Anzueto

given: Antonio

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: California Digital Library - eScholarship

repository_normalized: California Digital Library - eScholarship

repositories: California Digital Library - eScholarship

repositories_institution: California Digital Library - eScholarship

ReferenceCitation: Celli BR, Decramer M, Liu D, Metzdorf N, Asijee GM, Tashkin DP. Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial. Respir Res. 2016 May 4;17(1):48. doi: 10.1186/s12931-016-0361-4.

repositories_institution:
KU Leuven - Lirias
PubMed Central - Europe PMC

ReferenceCitation: Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Mölken MP. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014 Oct 18;14:163. doi: 10.1186/1471-2466-14-163.

repositories_institution:
Erasmus University, Rotterdam - RePub
PubMed Central - Europe PMC

ReferenceCitation: Tashkin DP, Li N, Kleerup EC, Halpin D, Celli B, Decramer M, Elashoff R. Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respir Res. 2014 Aug 31;15:102. doi: 10.1186/s12931-014-0102-5.

ReferenceCitation: Janssens W, Liu Y, Liu D, Kesten S, Tashkin DP, Celli BR, Decramer M. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT®). Respir Med. 2013 Sep;107(9):1409-16. doi: 10.1016/j.rmed.2013.04.015. Epub 2013 May 25.

repository_institution: University of North Carolina at Chapel Hill - Carolina Digital Repository

ReferenceCitation: Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD. 2012 Jun;9(3):289-96. doi: 10.3109/15412555.2012.656211. Epub 2012 Mar 20.

journal_name: COPD: Journal of Chronic Obstructive Pulmonary Disease

title: Efficacy of Tiotropium in COPD Patients with FEV1 ≥ 60% Participating in the UPLIFT® Trial

ReferenceCitation: Kesten S, Celli B, Decramer M, Liu D, Tashkin D. Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. Respir Res. 2011 Sep 28;12:129. doi: 10.1186/1465-9921-12-129.

title: Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial

ReferenceCitation: Tashkin D, Celli B, Kesten S, Lystig T, Decramer M. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med. 2010 Oct;104(10):1495-504. doi: 10.1016/j.rmed.2010.03.033. Epub 2010 Apr 24.

title: Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT® trial

ReferenceCitation: Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J. 2010 Jul;36(1):65-73. doi: 10.1183/09031936.00127809. Epub 2010 Feb 25.

name: on Behalf Of The Uplift(R) Investigators

title: Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT(R) trial

ReferenceCitation: Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009 Oct 3;374(9696):1171-8. doi: 10.1016/S0140-6736(09)61298-8. Epub 2009 Aug 27.

ReferenceCitation: Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.

repository_institution: University of Debrecen - University of Debrecen Electronic Archive

title: A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease

location_country:
Finland
Malaysia
Greece
Australia
Belgium
Russian Federation
Denmark
Czech Republic
Taiwan
France
Japan
Lithuania
Poland
Slovakia
Norway
Thailand
Argentina
Slovenia
South Africa
Hong Kong
Netherlands
Philippines
Switzerland
Singapore
Hungary
Ireland
Portugal
Germany
United States
United Kingdom
Italy
Austria
Brazil
Mexico
New Zealand
Spain
Turkey

location_facility: 205.235.3505 Istanbul Universitesi Tip Fakültesi

location_facility: 205.235.3615 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0434 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3711 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3810 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0719 Office of Pulmonology and Respiratory Diseases

location_facility: 205.235.3775 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1311 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0437 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0438 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1307 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2601 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1905 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1706 Juntendo University Hospital

location_facility: 205.235.3812 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0417 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1201 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3756 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1309 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0420 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3808 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3704 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0203 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0407 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3722 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1202 8th Pulmonology Clinic "Sotiria" Athens Chest Hospital

location_facility: 205.235.0814 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3739 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3608 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1645 Ospedale Civile "Zappatoni"

location_facility: 205.235.3741 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0723 Office of Pulmonary and Respiratory Diseases

location_facility: 205.235.3768 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0807 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0815 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3509 Atatürk Üniversitesi Tip Fakultesi Aziziye

location_facility: 205.235.3607 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0701 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3818 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0435 Boehringer Ingelheim Investigational Site

location_facility: 205.235.110 Hospital Privado - Centro Médico de Córdoba S.A.

location_facility: 205.235.3021 Hospital de Jerez de la Frontera

location_facility: 205.235.3025 Hospital Universitario Dr. Peset

location_facility: 205.235.3742 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1643 A. O. Santa Maria degli Angeli

location_facility: 205.235.2303 Veterans Memorial Medical Center

location_facility: 205.235.3707 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0831 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3019 Hospital Vírgen de la Macarena

location_facility: 205.235.3802 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0810 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3782 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3510 Cukurova Tip Fakultesi Balcali Hastanesi

location_facility: 205.235.3601 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0819 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3743 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3748 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3797 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3750 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1402 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3796 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0209 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3771 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2603 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3817 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1115 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3789 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0716 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0708 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3717 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1501 Boehringer Ingelheim Investigational Site

location_facility: 205.235.507 Depto.de Medicina Interna-Servico de pneumologia

location_facility: 205.235.0422 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0820 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3016 Hospital Universitari de Sant Joan

location_facility: 205.235.1303 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1320 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3745 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1206 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0711 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0403 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2301 Philippine General Hospital

location_facility: 205.235.0702 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1401 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3752 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3003 Hospital Clínic i Provincial de Barcelona

location_facility: 205.235.0712 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2604 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2403 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1904 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2406 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0827 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0713 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3784 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2202 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3758 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3814 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3603 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3734 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3804 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3719 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3723 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3026 Hospital General Universitario de Alicante

location_facility: 205.235.3004 Hospital General Universitario de Guadalajara

location_facility: 205.235.2204 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0703 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0413 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0305 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3764 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2901 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1306 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0830 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3800 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1207 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3208 Boehringer Ingelheim Investigational Site

location_facility: 205.235.105 Hospital General de Agudos José María Ramos Mejía

location_facility: 205.235.0211 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0301 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3792 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1106 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3205 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3508 Atatürk Gögüs Hastaliklari ve Gögüs Cerrahi

location_facility: 205.235.0412 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1503 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3713 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0705 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1006 Centre Hospitalier de Chauny

location_facility: 205.235.2802 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3760 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3770 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1209 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1505 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1906 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3033 Hospital General Carlos Haya

location_facility: 205.235.0207 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3793 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3616 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0835 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0205 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2504 Centro Hospitalar de Coimbra

location_facility: 205.235.3749 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3715 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3762 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3803 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1210 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1614 Ospedale Misericordia e Dolce

location_facility: 205.235.3813 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3201 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3507 Ankara SSK Diskapi Egitim Hastanesi

location_facility: 205.235.3738 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0704 Boehringer Ingelheim Investigational Site

location_facility: 205.235.515 Lar Escola São Francisco / Setor de Pneumologia

location_facility: 205.235.0428 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0824 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0423 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3301 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3403 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3404 Boehringer Ingelheim Investigational Site

location_facility: 205.235.504 ANEXO 2-Laboratório de Funcao Pulmonar

location_facility: 205.235.0826 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1109 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1310 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0903 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3730 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1316 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3604 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2805 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0406 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3779 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3402 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3727 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0206 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0201 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0808 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3610 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2409 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3020 Hospital Universitario La Paz

location_facility: 205.235.3303 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1308 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1802 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1313 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3787 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2804 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0710 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0801 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0720 Office of Pulmonology and Respiratory Diseases

location_facility: 205.235.2004 Edif. Dr. Rodrigo F. Barragan, P.B.

location_facility: 205.235.3816 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1105 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3815 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3809 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1403 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3736 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0901 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1617 Ospedale S. Camillo De Lellis

location_facility: 205.235.1203 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1112 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0821 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0805 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0421 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3751 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1025 Centre Médical Erdre Saint Augustin

location_facility: 205.235.1101 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0828 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1318 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3780 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0432 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3602 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3791 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3783 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1113 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0714 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1649 Ospedale di Circolo di Busto Arsizio

location_facility: 205.235.1315 Boehringer Ingelheim Investigational Site

location_facility: 205.235.514 Unidade de Coracao e Pulmao do Dto. de Medicina

location_facility: 205.235.0834 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2402 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0822 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3614 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3703 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3009 Hospital Clínico San Carlos

location_facility: 205.235.0414 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1301 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0811 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1901 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0832 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0813 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1102 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0709 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1648 Ospedale "S. Maria di Collemaggio"

location_facility: 205.235.3302 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2405 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0718 Clinic of Functional Diagnostics and Rehabilitation

location_facility: 205.235.3806 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2705 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2701 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3718 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3754 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1104 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3729 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3612 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1319 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3405 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1631 A. O. SS. Antonio e Biagio e Arrigo

location_facility: 205.235.3731 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1107 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0424 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0706 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2305 University of Santo Tomas Hospital

location_facility: 205.235.0816 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0833 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2702 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0904 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2404 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0202 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2703 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3204 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0212 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3035 Hospital Universitario Vírgen del Rocío

location_facility: 205.235.3732 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3706 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0707 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0303 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0402 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3716 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3011 Complejo Hospitalario Infanta Cristina

location_facility: 205.235.3759 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1312 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1903 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0429 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3744 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1114 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3725 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3018 Complejo Hospitalario Xeral - Cíes

location_facility: 205.235.2410 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3724 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0304 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1902 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2006 Tlalpan 4000, Pabellón 5, EPOC

location_facility: 205.235.1801 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1108 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0404 Boehringer Ingelheim Investigational Site

location_facility: 205.235.505 Dep.Medicina Especializada (DEMESP)

location_facility: 205.235.101 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1305 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2102 Martini Ziekenhuis Groningen

location_facility: 205.235.3757 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1710 Osaka City University Hospital

location_facility: 205.235.2801 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0405 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3202 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0806 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0804 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2407 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3037 Hsopital Universitario Ntra. Sra. de la Candelaria

location_facility: 205.235.0204 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2704 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2205 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2803 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3785 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3038 Hospital Clínico Lozano Blesa

location_facility: 205.235.3794 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2201 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3701 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3401 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0433 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3712 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1317 Boehringer Ingelheim Investigational Site

location_facility: 205.235.104 Hospital de Clinicas José de San Martín

location_facility: 205.235.0726 Private Office of Pulmonary Diseases

location_facility: 205.235.1211 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1302 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3014 Complejo Hospitalario Juan Canalejo

location_facility: 205.235.3737 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0902 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3002 Hospital Clínico Universitario de Valencia

location_facility: 205.235.3795 Boehringer Ingelheim Investigational Site

location_facility: 205.235.108 Hospital General de Agudos Dr. Enrique Tornú

location_facility: 205.235.3765 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3027 Complejo Asistencial Son Dureta

location_facility: 205.235.3781 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1314 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2408 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3788 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3773 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1009 Centre Hospitalier de Bigorre

location_facility: 205.235.3811 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3820 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1404 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0905 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0409 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3512 DokuzEylül Universitesi Tip Fakultesi Gögüs Hastaliklari ABD

location_facility: 205.235.3799 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3611 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3778 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0439 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1607 Università degli Studi di Sassari

location_facility: 205.235.2502 Centro Hospitalar de Vila Nova de Gaia

location_facility: 205.235.3790 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0809 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3039 Hospital Universitario Marqués de Valdecilla

location_facility: 205.235.3206 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0440 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3786 Pulmonary and Critical Care Medicine

location_facility: 205.235.0715 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3005 Hospital General San Jorge de Huesca

location_facility: 205.235.1205 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1204 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3609 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1702 Iwate Medical University Hospital

location_facility: 205.235.3502 Yedikule Gögüs Hastaliklari Hastanesi

location_facility: 205.235.3028 Hospital Universitario de la Princesa

location_facility: 205.235.0803 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1110 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0721 Office of Pulmonary Diseases

location_facility: 205.235.3721 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0302 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3807 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3006 Hospital Germans Trias i Pujol

location_facility: 205.235.1103 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3747 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2401 Boehringer Ingelheim Investigational Site

location_facility: 205.235.0802 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1304 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3511 Osmangazi Universitesi Tip Fakültesi

location_facility: 205.235.3501 Istanbul Universitesi Cerrahpasa Tip Fakultesi

location_facility: 205.235.3613 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1803 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2304 Lung Center of the Philippines

location_facility: 205.235.102 Instituto Cardiovascular de Rosario

location_facility: 205.235.2605 Boehringer Ingelheim Investigational Site

location_facility: 205.235.2602 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3761 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3763 Boehringer Ingelheim Investigational Site

location_facility: 205.235.3015 Corporació Sanitaria Parc Taulí de Sabadell

location_facility: 205.235.3605 Boehringer Ingelheim Investigational Site

location_facility: 205.235.1601 Presidio Ospedaliero di Cisanello


title: Open Label, Randomised Multicentre Phase III Study Of Irinotecan Hydrochloride (Campto (Registered)) And Cisplatin Versus Etoposide And Cisplatin In Chemotherapy Naive Patients With Extensive Disease - Small Cell Lung Cancer

summary: To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung Cancer (ED-SCLC).

lead_sponsor: Pfizer

location_country:
Italy
Austria
Switzerland
Netherlands
France
Poland
Belgium
Russian Federation
Egypt
Spain
Germany
Czech Republic
Taiwan


title: Pregabalin In Partial Seizures (Preps) : An Open-Label, International, Multicenter Add-On Therapy Trial

summary: To assess the clinical improvement (change in seizure frequency), safety and tolerability of patients with partial seizures following adjunctive therapy of pregabalin BID in addition to existing standard AEDs.

design_allocation: Non-Randomized

lead_sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

location_country:
Switzerland
Netherlands
Finland
Poland
France
Belgium
Portugal
United Kingdom


title: A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children

summary: The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among children at high risk for serious RSV disease. A secondary objective was to compare the incidence of medically-attended lower respiratory infections (LRIs) between treatment groups.

primary_purpose: Prevention

ReferenceType: result

ReferenceCitation: Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA; Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010 Jan;125(1):e35-51. doi: 10.1542/peds.2008-1036. Epub 2009 Dec 14.

family: Carbonell-Estrany

full_name: X. Carbonell-Estrany

family: Simoes

full_name: E. A. F. Simoes

given: E. A. F.

family: Dagan

full_name: R. Dagan

given: R.

family: Hall

full_name: C. B. Hall

given: C. B.

family: Harris

full_name: B. Harris

given: B.

family: Hultquist

full_name: M. Hultquist

given: M.

family: Connor

full_name: E. M. Connor

given: E. M.

family: Losonsky

full_name: G. A. Losonsky

given: G. A.

journal_name: PEDIATRICS

oa_host_type: repository

repository_institution: The University of Queensland - Queensland's institutional digital repository

version: submittedVersion

publisher: American Academy of Pediatrics (AAP)

publisher_dissemination: American Academy of Pediatrics (AAP)

publisher_group: American Academy of Pediatrics (AAP)

publisher_normalized: American Academy of Pediatrics (AAP)

title: Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial

lead_sponsor: MedImmune LLC

location_country:
Greece
Australia
Russian Federation
Denmark
Czech Republic
Iceland
France
Poland
Argentina
Canada
Chile
Sweden
Bulgaria
Hungary
Germany
United States
United Kingdom
Italy
Austria
Brazil
Israel
New Zealand
Spain
Turkey

location_facility: Wojewódzki Szpital Specjalistyczny, Oddział Dziecięcy

location_facility: Univ. S. Florida Pediatrics Ambulatory Care Center

location_facility: Multifunctional Hospital for Active Treatment "Pleven"

location_facility: Sioux Valley Hospital University of South Dakota Medical Center

location_facility: Dziecięcy Szpital Kliniczny im. Prof. dr hab. n. med. Antoniego Gębali w Lublinie

location_facility: University Of Alberta/Stollery Children's Hospital

location_facility: University Of Texas Health Science Center

location_facility: Hospital Clinico Universitario de Valencia

location_facility: Multifunctional Hospital for Active Treatment - Plovdiv

location_facility: Centre Hospitalier de L'Universite Laval

location_facility: Universitatsklinik fur Kinder und Jugenheilkunde, Graz

location_facility: Hippokration Hospital, University of Thessaloniki

location_facility: II Klinika Chorób Dzieci PAM, Samodzielny Publiczny

location_facility: Service de Medecine Neonatale et de reanimation pediatrique

location_facility: Children's Hospital Medical Center Of Akron

location_facility: Hospital Materno Infantil/Neumología pediátrica

location_facility: Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara

location_facility: Children's Respiratory Medicine Division of Maternal and Child Health Sciences Ninewells Hospital

location_facility: Manitoba Institute Of Child Health University of Manitoba

location_facility: James Whitcomb Riley Hospital for Children

location_facility: Centre Pediatrique Gatien de Clocheville

location_facility: Children's Healthcare D.B.A. Hospitals & Clinics

location_facility: Hospital e Maternidade Celso Pierro-Puccamp

location_facility: Wittenberg/Zentrum: fur Kinderheilkunde, Universitatsklinik und Poliklinik fur Kinder and Jugendmedizin

location_facility: Niepubliczny Zakład Opieki Zdrowotnej Salmed s.c.

location_facility: Specialized Hospital for Active Treatment of Obstetrics and Gynaecology"-"Maichin Dom"

location_facility: Ospedali Riuniti di Bergamo - Azienda Ospedaliera/Unità Operativa di Patologia Neonatale

location_facility: Katedra i Klinika Neonatologii AM w Poznaniu

location_facility: Borsod-Abaúj-Zemplén Megyei Önkormányzat Kórháza

location_facility: University of Michigan Mott Children's Hospital

location_facility: Hospital Universitario de Universidade de Sao Paulo

location_facility: Shands Hospital At The University Of Florida

location_facility: Beehly Medical Park Women's and Children's Pav.

location_facility: Paediatrisk Afdeling Herning Centralsygehus

location_facility: Hospital Peiade Interzonal General de Augodos

location_facility: Hospital Das Clinicas Da Faculdade De Medicina

location_facility: Zentrum Klinische Studien/Universtatsklinikum Freiburg

location_facility: Children's hospital, Landspitali University Hospital

location_facility: Azienda USL di Imola - Ospedale di Imola

location_facility: Kapiolani Medical Center for Woman and Children

location_facility: Wake Forest University School of Medicine

location_facility: Azienda Ospedaliera S. Maria della Misericordoa Struttura Operativa Complessa di Patologia Neonatale e terapia Intesiva Neonatale

location_facility: Asklepios Kinderklinik Sankt Augustin GmbH

location_facility: Klinik und Poliklinik und Jugendiche der Universitat Leipzig

location_facility: St. Petersburg State Pediatric Medical Academy

location_facility: Oddział Pediatrii i Kardiologii z pododdziałem Patologii Noworodka

location_facility: Saint-Petersburg State Pediatric Medical Academy

location_facility: Aristotele University of Thessaloniki, General "AXEPA" Hospital

location_facility: Szpital Morski im. PCK, Oddział Dziecięcy

location_facility: Hospital Sao Lucas da PUC-RS de Riberiao Perto da Universidade de Sao Paulo

location_facility: Azienda Sanitaria Ospedaliera O.I.R.M.-S. Anna

location_facility: Szpital Kliniczny nr 4 im.M.Konopnickiej, Oddział Intensywnej Terapii i Anestezjologii

location_facility: Samodzielny Publiczny Zakład Opieki Zdrowotnej Wojewódzki Szpital im. dr Jana Biziela w Bydgoszczy, Oddział Noworodków, Wcześniaków I Intensywnej Terapii Noworodka

location_facility: Georgia Pediatric Pulmonology Associates

location_facility: CHU Montpellier/Hoptial Arnaud de Villeneuve

location_facility: Hospital General De Ninos Pedro De Elizalde

location_facility: University Of Maryland School of Medicine

location_facility: Multifunctional Hospital for Active Treatment "St. Marina"

location_facility: Presio Ospedaliero di Alta Specializzazione "G. Salesi" - Azienda Ospedaliera Universitaria - Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"

location_facility: University Of Texas Houston Medical School

location_facility: Azienda Ospedaliera di Bologna - Policlinico S. Orsola - Malpighi

location_facility: University Multifunctional Hospital for Active Treatment "St. George" Clinic of Pediatrics

location_facility: University Multifunctional Hospital for Active Treatment "St. George" Neonatology Clinic

location_facility: St. Petersburg City Outpatient Hospital #45

location_facility: McGill University Health Centre Monteal Children's Hospital

location_facility: East Carolina University School of Medicine

location_facility: The Children's Clinic Of Jonesboro, P.A.

location_facility: University of Nebraska Medical Center Pediatric

location_facility: Queen's Medical Centre Nottingham University Hospital

location_facility: University Hospital State University of New York at Stony Brook Department of Pediatrics

location_facility: Univ. Of Texas Southwestern Medical Center

location_facility: Geisinger Medical Center- JW Children's Hospital

location_facility: Hospital Clinic y Maternistat - Barcelona

location_facility: Klinika Niemowlęca, Instytut Pomnik - Centrum Zdrowia Dziecka

location_facility: Pediatric Clinical Trials International, Inc.

location_facility: Universitatskinderlinik/Zentrum Fur klinische Studien

location_facility: Jefferson-duPont Children's Health Program

location_facility: Arkansas Children's Hospital Research Institute

location_facility: Fakultni Thomayerova nemocnice S poliklinkou

location_facility: Samodzielny Publiczny Szpital Kliniczny nr 1, Klinika Neonatologii

location_facility: Allgemeines KrankenHaus Universitatsklinkiken Wein

location_facility: CHU Bordeaux/Hopital des enfants/Unite de Neonatologie B

location_facility: Hospital Clinico Universitario de Santiago

location_facility: Klinika Neonatologii, Instytut Centrum Zdrowia Matki Polki

location_facility: Oddzial Kliniczny Kliniki Neonatologii Szpitala Uniwersyteckiego w Krakowie

location_facility: Azienda Ospedaliera Universitaria Policlinico Gaetano Martino

location_facility: Nemours Children's Clinic Biomedical Research

location_facility: Louisiana State University MidCity Clinic

location_facility: Hospital Clinico de la Universidad de Chile

location_facility: Ospedale Alessandro Manzoni Lecco - Presidio dell'Azienda Ospedaliera "Ospedale di Lecco"

location_facility: Specialized Hospital for Active Treatment of Cardio-vascular Diseases

location_facility: Hacettepe Üniversitesi İhsan Doğramacı Çocuk Hastanesi Neonatoloji Ünitesi

location_facility: Specialized Hospital for Active Treatment of Pediatric Diseases

location_facility: University of North Carolina-School of Medicine

intervention_type: Biological


title: Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

summary: The purpose of this clinical research study is to learn if Irbesartan is superior to placebo in reducing mortality and cardiovascular morbidity in subjects with heart failure with preserved systolic function. The safety of this treatment will also be studied.

ReferenceCitation: Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 4;359(23):2456-67. doi: 10.1056/NEJMoa0805450. Epub 2008 Nov 11.

family: Massie

full_name: Barry M. Massie

given: Barry M.

family: Carson

full_name: Peter E. Carson

given: Peter E.

family: McMurray

full_name: John J. McMurray

given: John J.

family: Komajda

full_name: Michel Komajda

given: Michel

family: McKelvie

full_name: Robert McKelvie

given: Robert

family: Zile

full_name: Michael R. Zile

given: Michael R.

family: Anderson

full_name: Susan Anderson

given: Susan

family: Donovan

full_name: Mark Donovan

given: Mark

family: Iverson

full_name: Erik Iverson

given: Erik

family: Staiger

full_name: Christoph Staiger

given: Christoph

family: Ptaszynska

full_name: Agata Ptaszynska

given: Agata

journal_name: New England Journal of Medicine

repositories_institution: The University of Queensland - Queensland's institutional digital repository

repositories_institution: University of Debrecen - University of Debrecen Electronic Archive

publisher: Massachusetts Medical Society

publisher_dissemination: Massachusetts Medical Society

publisher_group: Massachusetts Medical Society

publisher_normalized: Massachusetts Medical Society

title: Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction

ReferenceCitation: Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE; I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010 Mar 30;121(12):1393-405. doi: 10.1161/CIRCULATIONAHA.109.909614. Epub 2010 Mar 15.

name: From the RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Charleston (M.R.Z.); Lahey Clinic, Burlington, Mass (W.H.G.); University of Minnesota and VA Medical Center, Minneapolis (I.S.A.); Theresienkrankenhaus, Mannheim, Germany (M.H.); Wake Forest University School of Medicine, Winston-Salem, NC (J.C.L.); University of Florida–Shands Jacksonville, Jacksonville (A.B.M.); Hospital Universitario La Paz, IdiPaz, Madrid, Spain (J.L.-S.); University of...

family: Gaasch

full_name: William H. Gaasch

given: William H.

family: Anand

full_name: Inder S. Anand

given: Inder S.

family: Haass

full_name: Markus Haass

given: Markus

family: Little

full_name: William C. Little

given: William C.

family: Miller

full_name: Alan B. Miller

given: Alan B.

family: Lopez-Sendon

full_name: Jose Lopez-Sendon

given: Jose

family: Teerlink

full_name: John R. Teerlink

publisher: Ovid Technologies (Wolters Kluwer Health)

title: Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction

ReferenceCitation: McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008 Feb;10(2):149-56. doi: 10.1016/j.ejheart.2007.12.010.

name: Department of Cardiology, Western Infirmary, Glasgow, and Faculty of Medicine; University of Glasgow; Scotland UK

name: Washington Veterans Affairs Medical Center and Georgetown University; Washington DC USA

name: University Pierre et Marie Curie; Paris 6; Hôpital Pitiê-Salpêtrière Paris France

name: Medical University of South Carolina and Veterans' Affairs Medical Center; Charleston SC USA

name: Pharmaceutical Research Institute, Bristol Myers Squibb; Princeton NJ USA

name: Sanofi-Aventis; Bridgewater New Jersey USA

name: University of California and San Francisco Veterans Affairs Medical Center; San Francisco CA USA

title: Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial

ReferenceCitation: Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G; I-PRESERVE Investigators. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005 Oct;11(8):576-85.

ReferenceCitation: McKelvie RS, Komajda M, McMurray J, Zile M, Ptaszynska A, Donovan M, Carson P, Massie BM; I-Preserve Investigators. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail. 2010 Feb;16(2):128-34. doi: 10.1016/j.cardfail.2009.09.007. Epub 2009 Nov 4.

title: Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial

ReferenceCitation: Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Køber L, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clin Res Cardiol. 2021 Aug;110(8):1234-1248. doi: 10.1007/s00392-020-01786-8. Epub 2020 Dec 10.

repository_institution: The University of Glasgow - Enlighten: Publications

repositories_institution: The University of Glasgow - Enlighten: Publications

ReferenceCitation: Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 Aug 6;74(5):601-612. doi: 10.1016/j.jacc.2019.05.052.

journal_name: Journal of the American College of Cardiology

ReferenceCitation: Kristensen SL, Mogensen UM, Jhund PS, Rørth R, Anand IS, Carson PE, Desai AS, Pitt B, Pfeffer MA, Solomon SD, Zile MR, Køber L, McMurray JJV. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circ Heart Fail. 2019 Mar;12(3):e005766. doi: 10.1161/CIRCHEARTFAILURE.118.005766.

name: BHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (S.L.K., U.M.M., P.S.J., R.R., J.J.V.M.).

name: Department of Cardiology, Rigshospitalet University Hospital, Copenhagen, Denmark (S.L.K., U.M.M., R.R., L.K.).

name: Department of Medicine, University of Minnesota Medical School and Veterans Affairs Medical Center, Minneapolis (I.S.A.).

name: Department of Cardiology, Washington Veterans Affairs Medical Center, DC (P.E.C.).

name: Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (A.S.D., M.A.P., S.D.S.).

name: Division of Cardiology, Department of Medicine, University of Michigan School of Medicine, Ann Arbor (B.P.).

name: Medical University of South Carolina and Ralph H. Johnston Veterans Affairs Medical Center, Charleston (M.R.Z.).

name: On behalf of the I-Preserve and TOPCAT investigators

ReferenceCitation: Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Køber L, McKelvie RS, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray JJ. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017 Feb 21;135(8):724-735. doi: 10.1161/CIRCULATIONAHA.116.024593. Epub 2017 Jan 4.

name: From BHF Cardiovascular Research Centre, University of Glasgow, Scotland, UK (S.L.K., U.M.M., P.S.J., M.C.P., J.J.V.M.); Department of Cardiology, Rigshospitalet University Hospital, Copenhagen, Denmark (S.L.K., U.M.M., L.K.); Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK (D.P.); Mayo Clinic, Rochester, MN (S.W.); Western University, London, ON, Canada (R.S.M.); Ralph H. Johnsons Veterans Affairs Medical Center and...

ReferenceCitation: Gandhi PU, Chow SL, Rector TS, Krum H, Gaggin HK, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Carson PE, Januzzi JL Jr, Anand IS. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. J Card Fail. 2017 Jan;23(1):20-28. doi: 10.1016/j.cardfail.2016.06.006. Epub 2016 Jun 16.

ReferenceCitation: Badar AA, Perez-Moreno AC, Hawkins NM, Jhund PS, Brunton AP, Anand IS, McKelvie RS, Komajda M, Zile MR, Carson PE, Gardner RS, Petrie MC, McMurray JJ. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circ Heart Fail. 2015 Jul;8(4):717-24. doi: 10.1161/CIRCHEARTFAILURE.114.002024. Epub 2015 Jun 11.

name: From the BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (A.A.B., A.C.P.-M., P.S.J., A.P.T.B., R.S.G., M.C.P., J.J.V.M.); Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.A.B., R.S.G., M.C.P.); Division of Cardiology, University of British Columbia, Vancouver, Canada (N.M.H.); Veterans Affairs Medical Center and University of Minnesota, Minneapolis (I.S.A....

ReferenceCitation: Oluleye OW, Rector TS, Win S, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Massie B, Carson PE, Anand IS. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014 Nov;7(6):960-6. doi: 10.1161/CIRCHEARTFAILURE.114.001523. Epub 2014 Sep 15.

name: From the Department of Medicine, VA Medical Center and University of Minnesota, Minneapolis (O.W.O., T.S.R., S.W., I.S.A.); Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom (J.J.V.M.); Department of Medicine, RHJ Department of Veterans Affairs Medical Center, Medical University of South Carolina, Charleston (M.R.Z.); Institut de Cardiologie, Université Paris 6, Pitie Salpetriere Hospital, Paris, France (M.K.);...

repository_institution: Australian Catholic University - Research Bank

repositories_institution: Australian Catholic University - Research Bank

title: History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction

ReferenceCitation: Böhm M, Perez AC, Jhund PS, Reil JC, Komajda M, Zile MR, McKelvie RS, Anand IS, Massie BM, Carson PE, McMurray JJ; I-Preserve Committees and Investigators. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail. 2014 Jul;16(7):778-87. doi: 10.1002/ejhf.85. Epub 2014 May 23.

name: Universitätsklinikum des Saarlandes; Homburg/Saar Germany

name: BHF Glasgow Cardiovascular Research Centre; Institute of Cardiovascular and Medical Sciences, University of Glasgow; Glasgow UK

name: Université Paris 6 and Hospital Pitié-Salpêtrière; Paris France

name: Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina; Charleston USA

name: Hamilton Health Sciences; McMaster University; Hamilton ON Canada

name: Veterans Affairs Medical Center and University of Minnesota; Minneapolis MN USA

name: University of California, San Francisco, and San Francisco Veterans Affairs Medical Center; San Francisco USA

name: Georgetown University and Washington DC Veterans Affairs Medical Center; Washington DC USA

name: on behalf of the I-Preserve Committees and Investigators

ReferenceCitation: Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, McKelvie RS, McMurray JJ, Zile MR, Massie BM, Kitzman DW. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012 Sep 1;5(5):571-8. Epub 2012 Aug 10.

ReferenceCitation: Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, McKelvie RS, Komajda M, Kuskowski M, Massie BM; I-PRESERVE Trial Investigators. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 2012 Mar 1;5(2):217-25. doi: 10.1161/CIRCHEARTFAILURE.111.964221. Epub 2012 Jan 20.

name: From the Department of Veterans Affairs Health Care System and Department of Medicine, University of Minnesota, Minneapolis, MN (T.S.R., I.S.A.); the Department of Veterans Affairs Health Care System and Georgetown University Hospital, Washington, DC (P.E.C.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Scotland, United Kingdom (J.J.M.); Ralph H. Johnson Department of Veterans Affairs Medical Center and The Medical University of South Carolina, Charleston, SC (M.R...

title: Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial

ReferenceCitation: Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE; I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011 Dec 6;124(23):2491-501. doi: 10.1161/CIRCULATIONAHA.110.011031. Epub 2011 Nov 7.

name: From the RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, SC (M.R.Z., C.F.B.); University of Maryland Medical Center, Baltimore, MD (J.S.G.); University of Wisconsin School of Medicine and Public Health, Madison, WI (S.J.H.); British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK (J.J.M.); Université Paris 6; Pitié Salpêtrière Hospital, Paris, France (M.K.); Hamilton Health Sciences, McMaster...

title: Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction

ReferenceCitation: Krum H, Elsik M, Schneider HG, Ptaszynska A, Black M, Carson PE, Komajda M, Massie BM, McKelvie RS, McMurray JJ, Zile MR, Anand IS. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail. 2011 Sep;4(5):561-8. doi: 10.1161/CIRCHEARTFAILURE.110.960716. Epub 2011 Jul 12.

name: From the Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University/Alfred Hospital (H.K., M.E.), and Pathology Department, Alfred Hospital (H.G.S., M.B.), Melbourne, Victoria, Australia; Bristol-Myers Squibb, Princeton, NJ (A.P.); Georgetown University, Washington, DC (P.E.C.); Universite Paris 6, Paris, France (M.K.); University of California, San Francisco, and the San Francisco VA Medical Center, San Francisco, CA (B.M.M...

title: Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction

ReferenceCitation: Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011 Sep;4(5):569-77. doi: 10.1161/CIRCHEARTFAILURE.111.962654. Epub 2011 Jun 29.

name: From the VA Medical Center and University of Minnesota, Minneapolis, MN (I.S.A., T.S.R., M.K.); Department of Cardiology, University of Hull, Castle Hill Hospital, Kingston upon Hull, UK (J.G.C.); Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada (R.S.M.); Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden (H.P.); British Heart Foundation Glasgow Cardiovascular Research Center, Glasgow, UK (J.J.M.); RHJ Department of...

title: Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction

ReferenceCitation: Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011 May;4(3):324-31. doi: 10.1161/CIRCHEARTFAILURE.110.959890. Epub 2011 Feb 24.

name: From the Department of Cardiology, Theresienkrankenhaus, Mannheim, Germany (M.H.); Wake Forest University School of Medicine, Winston-Salem, NC (D.W.K.); VA Medical Center, Minneapolis, MN (I.S.A.); University of Florida, Jacksonville, FL (A.M.); Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, SC (M.R.Z.); University of California, San Francisco, and San Francisco VAMC, San Francisco, CA (B.M.M.); and Washington VAMC and Georgetown University,...

title: Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction

ReferenceCitation: Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011 Jan;4(1):27-35. doi: 10.1161/CIRCHEARTFAILURE.109.932996. Epub 2010 Nov 10.

name: From the Pitie Salpetriere Hospital–University Pierre and Marie Curie Paris VI (M.K.), Paris, France; Georgetown University and Washington DC Veterans Affairs Medical Center (P.E.C.), Washington, DC; the Department of Biostatistics and Medical Informatics (S.H.), University of Wisconsin-Madison, Madison, Wis; Hamilton Health Sciences (R.M.), McMaster University, Hamilton, Ontario, Canada; British Heart Foundation Glasgow Cardiovascular Research Centre (J.M.), University of Glasgow, Glasgow, United...

title: Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction

location_country:
Greece
Belgium
Australia
Russian Federation
Denmark
Czech Republic
France
Poland
Norway
Argentina
Canada
South Africa
Sweden
Switzerland
Netherlands
Hungary
Ireland
Portugal
Germany
United States
United Kingdom
Italy
Brazil
Mexico
Spain


title: A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen

summary:
PURPOSE:

The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory prostate cancer (HRPC).

TARGET PATIENT POPULATION:

The SPARC trial is intended for patients who have hormone-refractory prostate cancer (HRPC) and whose disease has progressed after treatment with one chemotherapy regimen. Please refer to the Eligibility Criteria page for the key inclusion and exclusion criteria.

WHAT IS SATRAPLATIN:

Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally. Satraplatin is also the only platinum-based drug that has demonstrated efficacy against prostate cancer in a randomized trial.

RATIONALE:

There are currently no approved chemotherapy drugs for the second line treatment of hormone-refractory prostate cancer (HRPC). In a preliminary randomized trial conducted in Europe, the combination of satraplatin and prednisone had superior activity compared to prednisone alone, for the treatment of HRPC patients who had not previously been treated with chemotherapy

lead_sponsor: Agennix

location_country:
Italy
Peru
Netherlands
Germany
Croatia
France
Poland
Israel
Hungary
Belgium
Argentina
Russian Federation
Spain
United States
United Kingdom

location_facility: LSU Health Science Center, Stanley S. Scott Cancer Center

location_facility: University of California Davis Cancer Center, Division of Hematology-Oncology

location_facility: Northern AZ Hematology & Oncology Assoc.

location_facility: Oddzial Chemioterapii, Bialostocki Osrodek Onkologiczny

location_facility: Maine Center for Cancer Medicine & Blood Disorders

location_facility: Hematology Oncology Associates of South Texas

location_facility: Centre Antoine Lacassagne Oncologie medicale

location_facility: Oddzial Radioterapii, Wielkopolskie Centrum Onkologii - Instytut

location_facility: Oddzial Chemioterapii, 4 Wojskowy Szpital Kliniczny

location_facility: Clinical Hospital Split Department of Oncology and Radiotherapy

location_facility: Hospital Italiano Regional del Sur Dept. Oncology

location_facility: University of Pittsburgh Cancer Institute- Hillman Cancer Center

location_facility: Klinika Nowotworow Ukladu Moczowego, Centrum Onkologii - Instytut

location_facility: Istituto Clinico Humanitas: Dipartimento di Oncologia Medica ed Ematologia

location_facility: Hospital Italiano de Cordoba Dept. Oncology

location_facility: Universitätsklinikum der Carl-Gustav-Carus Universität

location_facility: Oncology and Hematology Associates of West Broward P.A.

location_facility: Streekziekenhuis Koningin : Dept. Urology

location_facility: Hospital Ein Kerem Asaf Harofeh Medical Center

location_facility: Hospital Clínico San Carlos, Sevicio de Oncología Médica

location_facility: Capitol Comprehensive Cancer Care Clinic

location_facility: St. Bartholomew's Hospital Dept. of Medical Oncology

location_facility: Clinica Universitaria de Navarra, Sevicio de Oncología Médica

location_facility: Hôpital Saint-Louis: Service de Radiotherapy

location_facility: St George's Healthcare Dept of Oncology, Tooting

location_facility: Sharp Healthcare - Clinical Oncology Research

location_facility: Instituto Valenciano de Oncología: Sevicio de Oncología Médica

location_facility: Hospital Universitario Marqués de Valdecilla, Sevicio de Oncología Médica

location_facility: Texas Oncology, P.A. - Deke Slayton Cancer Center

location_facility: University of Pennsylvania Abramson Cancer Center

location_facility: Hematology/Oncology Group of South Florida

location_facility: Salisbury Investigaciones Clinicas del Grupo CER S.A.

location_facility: Academisch Ziekenhuis Nijmegen: Urology Department

location_facility: Istituto Nazionale per la Ricerca sul Cancro (IST)

location_facility: Hospital Clinic i Provincial, Sevicio de Oncología Médica

location_facility: Hematology/Oncology Associates of Treasure Coast

location_facility: Klinikum der Philipps - Universitat Marburg

location_facility: Stadtische Klinicen Frankfurt a.M. Hochst

location_facility: Oddzial Onkologii I Radioterapii, Szpital Morski im. PCK

location_facility: Institut Jules Bordet Service de Chimiothérapie

location_facility: Hospital de la Santa Creu i Sant Pau, Sevicio de Oncología Médica

location_facility: Nebraska Methodist Hospital Cancer Center

location_facility: Hematology and Oncology Associates of Northeastern PA / PC

location_facility: Medical University of South Carolina Hollings Cancer Center

location_facility: Klinikum der medizinischen Fakultät der Martin-Luther-Universität Halle-Wittenberg

location_facility: Universita degli Studi di Napoli Federico II-Nuovo Policlinico

location_facility: Academic Hospital of the University of Amsterdam

location_facility: Medical Radilogical Research Center of Rams

location_facility: Klinickum der Johannes-Gutenberg Universitat

location_facility: Hôpital de La Tronche - CHU de Grenoble: Departement de cacerologie et d'hematologie

location_facility: Clinical Hostpital Rebro Department of Oncology

location_facility: Policlinica Bancaria "9 de Julio" Av. Gaona 2197

location_facility: Innovative Medical Research of South Florida

location_facility: Karmanos Cancer Institute, Wayne State University


title: An International, Prospective Cohort to Document the Effectiveness of One BoNT-A Injection Cycle Based on Attainment of Individual Person-centred Goals in Adult Subjects Suffering From Upper Limb Spasticity Following Stroke

summary: The purpose of the study is to assess the responder rate as defined by the achievement of the primary goal from the Goal Attainment Scale following one BoNT-A injection cycle in accordance with routine practices.

study_type: Observational

time_perspective: Prospective

ReferenceCitation: Fheodoroff K, Ashford S, Jacinto J, Maisonobe P, Balcaitiene J, Turner-Stokes L. Factors influencing goal attainment in patients with post-stroke upper limb spasticity following treatment with botulinum toxin A in real-life clinical practice: sub-analyses from the Upper Limb International Spasticity (ULIS)-II Study. Toxins (Basel). 2015 Apr 8;7(4):1192-205. doi: 10.3390/toxins7041192.

family: Fheodoroff

full_name: Klemens Fheodoroff

given: Klemens

family: Ashford

full_name: Stephen Ashford

given: Stephen

family: Jacinto

full_name: Jorge Jacinto

given: Jorge

family: Maisonobe

full_name: Pascal Maisonobe

given: Pascal

family: Balcaitiene

full_name: Jovita Balcaitiene

given: Jovita

family: Turner-Stokes

full_name: Lynne Turner-Stokes

given: Lynne

currency_apc_doaj: CHF

journal_name: Toxins

repository_institution: PubMed Central - Europe PMC

evidence: oa repository (semantic scholar lookup)

publisher: MDPI AG

publisher_dissemination: MDPI

publisher_group: MDPI

publisher_normalized: MDPI

title: Factors Influencing Goal Attainment in Patients with Post-Stroke Upper Limb Spasticity Following Treatment with Botulinum Toxin A in Real-Life Clinical Practice: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study

ReferenceCitation: Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P. Results from the Upper Limb International Spasticity Study-II (ULISII):a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. BMJ Open. 2013 Jun 20;3(6). pii: e002771. doi: 10.1136/bmjopen-2013-002771.

journal_name: BMJ Open

license: cc-by-nc

license_normalized: cc-by-nc

repositories_institution:
King's College London - Research Portal
PubMed Central - Europe PMC

title: Results from the Upper Limb International Spasticity Study-II (ULIS-II): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management

ReferenceCitation: Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P, Zakine B. Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice. BMJ Open. 2013 Mar 18;3(3). pii: e002230. doi: 10.1136/bmjopen-2012-002230.

location_country:
Finland
Malaysia
Australia
Belgium
Russian Federation
Denmark
Taiwan
France
Thailand
Korea, Republic of
Sweden
Philippines
Singapore
China
Portugal
Germany
United Kingdom
Italy
Austria
Mexico
Czechia
Spain

location_facility: Samsung Medical Center, #50 Ilwon-dong, Gangnam-gu (site 410002)

location_facility: Singapore General Hospital, Department of Rehabilitation Medicine (site 702002)

location_facility: Hôpital Jean Minjoz/Méd.physique réadaptation (site 250016)

location_facility: CHU Lapeyronie /Rééducation fonctionnelle (site 250014)

location_facility: Kliniken der Medizinischen Hochschule (Neurologische Klinik), Carl-Neuberg-Str. 1 (site 276005)

location_facility: Centre de Rééducation Fonctionnelle du Mont Veyrier Rééducation fonctionnelle (site 250021)

location_facility: Herlev Hospital, Herlev Ringvej (Site 208004)

location_facility: Federal State Institution "Medical Rehabilitation Centre of Roszdrav" (site 643001)

location_facility: Hôpital Timone Adultes/Rééducation fonctionnelle (site 250020)

location_facility: Médecine Physique et de Réadaptation Fondation Hospitalière Sainte Marie (site 250001)

location_facility: State Educational Institution of high professional education "St-Peterbusrg state medical university named after I.P. Pavlov of Roszdrav" (site 643003)

location_facility: CHRU Lille/Rééducation Neurologique (site 250018)

location_facility: State Novosibirsk Regional Clinical Diagnostic Centre (site 643005)

location_facility: Hospital Marqués de Valdecilla/ Servicio de Rehabilitación (site 724009)

location_facility: Paracelsus Klinik Werdauer Str. 68 (site 276002)

location_facility: Hospital Morales Meseguer / Servicio de Rehabilitación (site 724005)

location_facility: Tan Tock Seng Hospital/TTSH Rehabilitation Centre (site 702001)

location_facility: Ryde Rehabilitation Center (site 036002)

location_facility: Catholic University Daejeon St. Mary's Hospital, Daeheung-dong, Jung-gu, (site 410004)

location_facility: Hôpital Pellegrin/Rééducation fonctionnelle (site 250012)

location_facility: Dept. of Rehabilitation Yonsei University Severance Hospital (site 410001)

location_facility: CHU de Nantes/Médecine physique et de réadaptation neurologique (site 250017)

location_facility: Praxis für Neurologie, Dalberger Str. 6 (site 276007)

location_facility: Ospedale Valduce, Costa Masnaga (site 380001)

location_facility: Northshore Private Hospital (site 036003)

location_facility: State Institution "Interregional clinical diagnostic centre" (site 643002)

location_facility: CHU Hôpital SUD/Institut de Rééducation (site 250007)

location_facility: Sächs. KH Neurologie, Hufelandstr. 15 (site 276006)

location_facility: Rehabilitation Unit, Tung Wah Hospital, 12 Po Yan Street, Sheung Wan (site 344001)

location_facility: State Educational Institution of high professional education "Krasnoyarsk State Medical Academy of Roszdrav" (site 643007)

location_facility: Regional Rehabilitation Unit, Northwick Park Hospital (site 826006)

location_facility: Hopital Jean Rebeyrol/Médecine Physique et de Réadaptation (site 250006)

location_facility: Municipal health care institution "City hospital #2 "Krasnodar Multidisciplinary medical diagnostic association" (site 643004)

location_facility: Dept. for Rehabilitation Asan Medical Center (site 410005)

location_facility: West Midlands/Rehabilitation Centre (826005)

location_facility: Inha University Hospital, #7-206 Shinheungdong-ga,Jjung-gu (site 410006)

location_facility: Universiti Malaya Medical Center/Department of Neurology / Department of Rehabilitation Medicine (site 458001)

location_facility: Hospital Distrital de Faro (site 620004)

location_facility: Neurologisk afdeling N, Amtssygehuset i Glostrup (Site 208003)

location_facility: Perpetual Succour Hospital (site 608002)

location_facility: Dewsbury District Hospital (site 826004)

location_facility: King Chulalongkorn Memorial Hospital/Department of Rehabilitation Medicine (site 764002)

location_facility: Laboratorio analisi del Movimento U.O.R.R.F. -Ospedale Santa Corona (site 380002)

location_facility: Dept. of Rehabilitation Seoul National University Bundang Hospital (site 410003)

location_facility: Hospital Pardubice, Neurology dept. (site 203001)

location_facility: Aarhus University Hospital, Neurolog avd.F-NEU-Cent (Site 208001)

location_facility: Centre Régional de Rééducation et Réadaptation fonctionnelle (site 250008)

location_facility: Hôpital Hautepierre/Rééducation fonctionnellev (site 250011)

location_facility: Royal Prince Alfred Hospital (site 036005)

location_facility: Dept. Of Neurology, Nyköping Hospital (site 752002)

location_facility: Centre Médico-Chirurgical de Réadaptation des Massues (Site 250005)

location_facility: Metropolitan Medical Center (site 608001)

location_facility: Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental (site 620003)

location_facility: Hospital La Paz / Servicio de Rehabilitación (site 724006)

location_facility: NÖ LKH Grimmenstein-Hochegg (site 040002)

location_facility: Hôpital Sébastopol/Rééducation Fonctionnelle (site 250004)

location_facility: Hôpital Pontchaillou/Rééducation Fonctionnelle (site 250003)

location_facility: Municipal health care institution "City clinical hospital #3" (site 643006)

location_facility: Centro de Medicina de Reabilitação de Alcoitão (site 620001)

location_facility: Centre Médecine Physique Réadaptation/Rééducation Neurologique (site 250013)

location_facility: NRZ Neurologisches Rehazentrum (site 276004) Muldentalweg 1

location_facility: Azienda Ospedaliera Universitaria (site 380012)

location_facility: Läkarhuset Odenplan, Neuro Unit (site 752003)

location_facility: Hopital Albert Chenevier/Neurologie, (site 250010)

location_facility: Praxis für Neurologie Mittelstr. 4 (site 276008)

location_facility: Cliniques Universitaires UCL de Mont-Godinne, Avenue Dr. G. Therasse (site 056003)

location_facility: Hôpital Rangueil/Médecine Physique réadaptation (site 250015)

location_facility: Kinik für Neurologie Paracelsusring 6a (site 276003)

location_facility: UCL St. Luc Département de médecine, physique et de readaptation motrice, Avenue Hippocrate 10 (site 056004)

location_facility: Invalidförbundets Rehabiliteringscenter i Lappland (Site 246004)

location_facility: Clinica di Neuroriabilitatione - Az. Osp. Univ. Ospedali Riuniti (site 380004)

location_facility: Hospital Universitario La Fe (Site 724003)

location_facility: Siriraj Hospital/Department of Rehabilitation Medicine (site 764001)

location_facility: Hospital Geral de Santo Antonio, Centro Hospitalar do Porto (site 620002)

location_facility: Centro Hospitalar de Coimbra - Quinta dos Vales (site 620005)

location_facility: Department of Physical and Rehabilitation Medicine/Central Hospital of Central Finland (Site 246005)

location_facility: AZ St. Jan, Ruddershove 10, (site 056002)

location_facility: Hôpital Raymond Poincaré/Rééducation neurologique (site 250002)

location_facility: China Medical University Hospital, Department of Physical Medicine & Rehabilitation (site 158002)

location_facility: Neurologiska Polikliniken, Tampere University Hospital (site 246001)

location_facility: Revalidatieziekenhuis Hof ter Schelde, August Vermeylenlaan 6 (site 056001)

location_facility: Mälarsjukhuset, Dept. Of Neurology (site 752001)


type: Other Identifier

title: A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pretreatment At the Time of Diagnosis in Patients With Non-ST-Elevation Myocardial Infarction (NSTEMI): The ACCOAST Study

acronym: ACCOAST

summary: The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary angiography/percutaneous coronary intervention (PCI).

ReferenceCitation: Silvain J, Rakowski T, Lattuca B, Liu Z, Bolognese L, Goldstein P, Hamm C, Tanguay JF, Ten Berg J, Widimsky P, Miller D, Portal JJ, Collet JP, Vicaut E, Montalescot G, Dudek D; ACCOAST Investigators. Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2019 Mar 5;73(8):906-914. doi: 10.1016/j.jacc.2018.11.055.

family: Silvain

full_name: Johanne Silvain

given: Johanne

family: Rakowski

full_name: Tomasz Rakowski

given: Tomasz

family: Lattuca

full_name: Benoit Lattuca

given: Benoit

family: Liu

full_name: Zhenyu Liu

given: Zhenyu

family: Bolognese

full_name: Leonardo Bolognese

given: Leonardo

family: Goldstein

full_name: Patrick Goldstein

given: Patrick

family: Hamm

full_name: Christian Hamm

given: Christian

family: Tanguay

full_name: Jean-Francois Tanguay

given: Jean-Francois

family: ten Berg

full_name: Jur ten Berg

given: Jur

family: Widimsky

full_name: Petr Widimsky

given: Petr

full_name: Debra Miller

given: Debra

family: Portal

full_name: Jean-Jacques Portal

given: Jean-Jacques

family: Collet

full_name: Jean-Philippe Collet

given: Jean-Philippe

family: Vicaut

full_name: Eric Vicaut

given: Eric

family: Montalescot

full_name: Gilles Montalescot

given: Gilles

family: Dudek

full_name: Dariusz Dudek

given: Dariusz

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inserm

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Diderot

title: Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non–ST-Segment Elevation Myocardial Infarction

ReferenceCitation: Porto I, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, Ten Berg J, Widimský P, Le Gall N, Zagar AJ, LeNarz LA, Miller D, Montalescot G; ACCOAST Investigators. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy. JACC Cardiovasc Interv. 2016 May 9;9(9):897-907. doi: 10.1016/j.jcin.2016.01.041.

family: Porto

full_name: Italo Porto

given: Italo

title: Impact of Access Site on Bleeding and Ischemic Events in Patients With Non–ST-Segment Elevation Myocardial Infarction Treated With Prasugrel

ReferenceCitation: Dudek D, Dziewierz A, Widimsky P, Bolognese L, Goldstein P, Hamm C, Tanguay JF, LeNarz L, Miller DL, Brown E, Ten Berg J, Montalescot G; ACCOAST Investigators. Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study. Am Heart J. 2015 Nov;170(5):1025-1032.e2. doi: 10.1016/j.ahj.2015.07.017. Epub 2015 Jul 26.

title: Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non–ST-Elevation Myocardial Infarction (ACCOAST) study

ReferenceCitation: Widimsky P, Motovska Z, Bolognese L, Dudek D, Hamm C, Tanguay JF, Ten Berg J, Brown E, LeNarz L, Miller DL, Montalescot G; ACCOAST Investigators. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart. 2015 Aug;101(15):1219-24. doi: 10.1136/heartjnl-2015-307686. Epub 2015 Jun 9.

ReferenceCitation: Montalescot G, Collet JP, Ecollan P, Bolognese L, Ten Berg J, Dudek D, Hamm C, Widimsky P, Tanguay JF, Goldstein P, Brown E, Miller DL, LeNarz L, Vicaut E; ACCOAST Investigators. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. J Am Coll Cardiol. 2014 Dec 23;64(24):2563-2571. doi: 10.1016/j.jacc.2014.08.053.

title: Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI

ReferenceCitation: Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013 Sep 12;369(11):999-1010. doi: 10.1056/NEJMoa1308075. Epub 2013 Sep 1.

title: Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

ReferenceCitation: Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg J, Widimsky P, Luo J, Miller DL, Goedicke J. A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. Am Heart J. 2011 Apr;161(4):650-656.e1. doi: 10.1016/j.ahj.2010.10.017. Epub 2011 Feb 25.

title: A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non–ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study

location_country:
Italy
Austria
Sweden
Netherlands
Germany
Finland
France
Poland
Lithuania
Israel
Slovakia
Romania
Hungary
Belgium
Latvia
Portugal
Turkey
Canada
Czech Republic

location_facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.